No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Novālent is HACCP Certified

Editor: What To Know

  • “Spending time on this certification—and it is a significant time and resources investment—is indicative of a company seeking to modernize its approach to food safety requirements.
  • Novālent film technology is for use as a residual antimicrobial under EPA and FDA regulations to preserve food contact surfaces and is used by leading firms including PepsiCo, Sabra, and Pilgrims.
  • This is a big deal when it comes to adding another layer of food safety for our food and beverage customers.

December 9, 2020

Novālent reports its facilities are Hazard Analysis Critical Control Point (HACCP) certified.

“Earning the GMP/HACCP certification in our manufacturing plant is a competitive advantage. This is a big deal when it comes to adding another layer of food safety for our food and beverage customers. In today’s world where there is a heightened awareness for food protection, this certification becomes extremely valuable to the entire food chain.” Mike Motta, Chief Commercial Officer at Novālent, explains.

HACCP certification is an internationally recognized list of requirements established by the Food Safety Modernization Act (FSMA) and Global Food Safety Initiatives (GFSI) standards.

Achieving the certification confirms a company employs effective control of food safety throughout its processes. The principles of this certification are often used to update food safety legislation in countries around the world.

Novālent was assisted in this achievement by Darryle Guarino, CEO at GFSC Group, Inc. who says going through this process is indicative of a modern biochemical company’s dedication to safety.

“Spending time on this certification—and it is a significant time and resources investment—is indicative of a company seeking to modernize its approach to food safety requirements.”

Novālent film technology is for use as a residual antimicrobial under EPA and FDA regulations to preserve food contact surfaces and is used by leading firms including PepsiCo, Sabra, and Pilgrims. Novālent antimicrobial creates an invisible film that stays active and anchored through day to day operations. One application lasts up to 90 days and through multiple cleaning cycles. The company also offers a hand sanitizer.

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy